COMMUNIQUÉS West-GlobeNewswire

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
09/02/2026
– First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million – First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million – Conference [...]
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
09/02/2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the [...]
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
09/02/2026
TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary [...]
Context Therapeutics to Participate in Upcoming Investor Conferences
09/02/2026
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
BioSyent to Acquire Oral Science Inc.
09/02/2026
Accretive Transaction with Combined Companies’ Pro-Forma Revenue in Excess of $70.00 Million and EBITDA (1) in Excess of $15.75 Million (TTM Sept 30, 2025) MISSISSAUGA, Ontario, Feb. 09, 2026 (GLOBE NEWSWIRE) -- [...]
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
09/02/2026
DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
BioPorto A/S Appoints Chief Financial Officer
09/02/2026
February 9, 2026 Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and [...]
Avacta appoints Francis Wilson as Chief Scientific Officer
09/02/2026
LONDON and PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology [...]
Notification of managers’ transactions
09/02/2026
ANNOUNCEMENT NO. 301 9 February 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
09/02/2026
Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated [...]
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
09/02/2026
PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by [...]
Bavarian Nordic – Completion of Share Buy-Back Program
09/02/2026
COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate [...]
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
09/02/2026
Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi for warm [...]
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
09/02/2026
Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds
09/02/2026
Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le rilzabrutinib est le [...]
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
09/02/2026
BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
09/02/2026
TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Fangzhou Wins Tencent Health ‘AI-Powered Future Award’ as MaaS Platform Drives AI Chronic Care
09/02/2026
SHANGHAI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, has won the “AI-Powered Future Award” at a high-level industry [...]
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
08/02/2026
Campaign debuted during Super Bowl LX and introduced www.NextInMS.com , a new platform designed to create space for honest conversation among people living with MS A Media Snippet accompanying this announcement is [...]

Pages